Thompson Ernest St John, Howe Elizabeth, Kenworthy LaMarca Tara, Natale Ruby, Jent Jason F
Mailman Center for Child Development, Department of Pediatrics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
J Clin Med. 2024 Apr 16;13(8):2299. doi: 10.3390/jcm13082299.
On 18 June 2022, Moderna and Pfizer-BioNTech COVID-19 vaccines were authorized under an Emergency Use Authorization by the United States Food and Drug Administration to prevent severe coronavirus disease in children six months to four years of age. Despite approval of the COVID-19 vaccinations for young children, there remain ongoing challenges reaching widespread coverage due to parental decision-making. Parental decision-making plays a pivotal, yet understudied, role governing vaccine adoption among this priority demographic. This cross-sectional analysis examined COVID-19 vaccine intentions for 320 predominately Hispanic parents of two to five-year-olds attending Miami-Dade County childcare programs in Florida USA, several months following the June 2022 emergency authorization. Parent's self-reported survey data encompassed vaccine choices and rationales, social determinants of health, and parent immigrant status. Data analyses illustrate the associations between parent decision-making and these variables. Regression modeling and tests of independence identified predicting factors for parental vaccine decision-making. Only 25% of parents intended to vaccinate their young child, while 34% resisted and 41% felt unsure, despite 70% personal vaccination rates. Household income under $25,000, identifying as a migrant, or testing COVID-19-positive significantly predicted unsure decision-making. The majority of hesitant groups expressed concerns around side effects (20%), safety (2.9%), and sufficiency of vaccine knowledge (3.3%). In this sample, the predominance of parents were unsure and resistant rather than accepting of having their child vaccinated despite emergency approval of the pediatric vaccine. Associations and predictive factors are examined.
2022年6月18日,美国食品药品监督管理局根据紧急使用授权批准了莫德纳和辉瑞 - 生物科技公司的新冠疫苗,用于预防6个月至4岁儿童的重症冠状病毒病。尽管新冠疫苗已获批准用于幼儿,但由于父母的决策,在实现广泛接种方面仍面临持续挑战。父母的决策在这一优先人群的疫苗接种中起着关键作用,但尚未得到充分研究。这项横断面分析调查了2022年6月紧急授权几个月后,美国佛罗里达州迈阿密 - 戴德县参加儿童保育项目的320名主要为西班牙裔的两到五岁儿童的父母的新冠疫苗接种意愿。父母的自我报告调查数据包括疫苗选择和理由、健康的社会决定因素以及父母的移民身份。数据分析阐明了父母决策与这些变量之间的关联。回归建模和独立性检验确定了父母疫苗决策的预测因素。尽管个人接种率达70%,但只有25%的父母打算为其幼儿接种疫苗,34%的父母拒绝接种,41%的父母不确定是否接种。家庭收入低于25,000美元、被认定为移民或新冠病毒检测呈阳性显著预测了不确定的决策。大多数犹豫不决的群体对副作用(20%)、安全性(2.9%)和疫苗知识的充分性(3.3%)表示担忧。在这个样本中,尽管儿科疫苗已获紧急批准,但大多数父母不确定且拒绝让孩子接种疫苗。研究了其中的关联和预测因素。